000 01441 a2200409 4500
005 20250517163436.0
264 0 _c20171117
008 201711s 0 0 eng d
022 _a1744-7674
024 7 _a10.1080/13543776.2017.1355908
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMusumeci, Francesca
245 0 0 _aPyrrolo[2,3-d]pyrimidines active as Btk inhibitors.
_h[electronic resource]
260 _bExpert opinion on therapeutic patents
_cDec 2017
300 _a1305-1318 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAgammaglobulinaemia Tyrosine Kinase
650 0 4 _aAnimals
650 0 4 _aAutoimmune Diseases
_xdrug therapy
650 0 4 _aDrug Design
650 0 4 _aHumans
650 0 4 _aLeukemia, B-Cell
_xdrug therapy
650 0 4 _aLymphoma, B-Cell
_xdrug therapy
650 0 4 _aPatents as Topic
650 0 4 _aProtein Kinase Inhibitors
_xchemistry
650 0 4 _aProtein-Tyrosine Kinases
_xantagonists & inhibitors
650 0 4 _aPyrimidines
_xchemistry
650 0 4 _aPyrroles
_xchemistry
700 1 _aSanna, Monica
700 1 _aGreco, Chiara
700 1 _aGiacchello, Ilaria
700 1 _aFallacara, Anna Lucia
700 1 _aAmato, Rosario
700 1 _aSchenone, Silvia
773 0 _tExpert opinion on therapeutic patents
_gvol. 27
_gno. 12
_gp. 1305-1318
856 4 0 _uhttps://doi.org/10.1080/13543776.2017.1355908
_zAvailable from publisher's website
999 _c27365138
_d27365138